GHRP-2 pretreatment directly protected against myocardial stunning (post-ischemic diastolic dysfunction) in an isolated heart model, while recombinant GH did not, proving the cardioprotective effect is independent of growth hormone.
GH not neededGHRP-2 protected hearts from stunning while growth hormone did not — the cardiac benefit is direct, not through GH, making it a pure cardioprotective agent
What the researchers found
GHRP-2 pretreatment directly protected against diastolic myocardial stunning in isolated hearts, while recombinant GH did not, demonstrating GH-independent, direct cardiac protection through cardiac GH secretagogue receptors.
Why it matters
Direct cardiac protection by GHRP-2 — independent of GH — means it could be used during cardiac surgery or heart attacks to prevent stunning damage without the risks of GH therapy.
How the study worked
Animal study using isolated, blood-perfused rabbit hearts. GHRP-2 or rhGH administered before ischemia-reperfusion protocol. Diastolic and systolic function measured by pressure-volume analysis.
What this study cannot tell us
Isolated heart model lacks normal circulatory and hormonal context. Rabbit hearts may differ from human. Acute pretreatment protocol — clinical application timing is challenging.
How to read the evidence
Moderate evidence from a controlled isolated heart study with clear comparison between GHRP-2 and GH, demonstrating GH-independent cardioprotection.
When this study was published
Published in 2000. The direct cardioprotective effects of GH secretagogues have been further characterized, linked to cardiac CD36 receptors.
The bigger picture
The separation of GHRP-2's cardiac protection from its GH-releasing effect is therapeutically significant. It means cardioprotective GH secretagogues could be developed specifically for heart protection without hormonal side effects.
Questions still open
- Could GHRP-2 be given before cardiac surgery to prevent stunning?
- Which cardiac receptor mediates the direct protective effect?
- Does the protection extend to irreversible ischemic injury, not just stunning?
Common questions
Can GHRP-2 protect the heart during a heart attack?
Why is GH independence important?
Read the original research
Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model.
Endocrinology, 141(11), 3993-9
Citation
Weekers, F; Van Herck, E; Isgaard, J; Van den Berghe, G. (2000). Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model.. Endocrinology, 141(11), 3993-9.